课题基金 / 基金详情

PNU 214936 IN ADVANCED ADENOCARCINOMAS OF THE BREAST

PNU 214936 IN ADVANCED ADENOCARCINOMAS OF THE BREAST
PNU 214936 用于晚期乳腺癌
批准号：
6303006
负责人：
James A Posey
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303006
关键词：
adenocarcinoma antineoplastics breast neoplasms clinical research clinical trials dosage human subject human therapy evaluation neoplasm /cancer chemotherapy neoplastic growth

项目摘要

项目成果

James A Posey的其他基金

相似基金

相关文献

中文摘要
翻译
PNU-214936是针对糖蛋白5T4的Fab片段，该糖蛋白与突变的超抗原化学连锁。这项研究使用了每天3小时的X4输液。如果疾病进展、毒性或免疫反应不排除，患者可以接受第二个疗程。主要毒副反应为发热、局部炎症反应、治疗中或治疗后短期内寒战。17例治疗后无反应。
英文摘要
PNU-214936 a Fab fragment directed against a glycoprotein 5T4 chemically linked to a mutated superantigen. This study utilized a 3 hours daily X 4 infusion. Patients could receive a second course if not precluded by disease progression, toxicity or immune response. The principal toxicities were fever, local inflammatory reaction, chills during or shortly after the treatment. No responses were observed in 17 treated patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UAB 0282 GEMCITABINE
Rebeccamycin in hepatabiliary cancers
TAXOTERE W/ CONTINUOUS INFUSION TOPOTECAN IN ADVANCED MALIGNANCIES
PNU 214936 IN ADVANCED ADENOCARCINOMAS OF THE BREAST
海外基金